Effect of Casodex on Tumour Hypoxia - Prostate Cancer

Not Applicable

Completed

Brief Summary: Prostate cancers, in common with many other tumours, are often hypoxic; that is, they have low levels of oxygen. It is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment. One previous study has suggested that hormone therapy, such as Casodex, may improve the prostate oxygen level. This study is designed to test that finding.

Recruitment & Eligibility

Inclusion Criteria

Men with histologically proven prostatic carcinoma, stage cT2, N0, M0, receiving neoadjuvant bicalutamide plus conformal radiotherapy in study 9907, who have previously participated in the prostate cancer hypoxia project
informed consent

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
hypoxia measurement	hypoxia measurement	Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy

Primary Outcome Measures

Name	Time	Method
Correlate level of tumor oxygenation with prostate volume	8 weeks	prostate volume measurement
Correlate level of tumor oxygenation with hemoglobin level	8 weeks	hemoglobin test (g/L)
To determine the effect of neoadjuvant anti-androgen therapy on oxygenation of prostatic tumours	8 weeks	Trans-rectal ultrasound and measurement of tumor oxygenation
Correlate level of tumor oxygenation with PSA level	8 weeks	PSA test (ug/L)

Secondary Outcome Measures

Name	Time	Method
To study of the effect of neoadjuvant anti-androgen therapy on prostate tumour histopathology and gene expression, and correlation of these effects with changes in oxygenation.	8 weeks

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial